Peter Dreger
#155,440
Most Influential Person Now
Researcher
Peter Dreger's AcademicInfluence.com Rankings
Peter Dregercomputer-science Degrees
Computer Science
#8507
World Rank
#8943
Historical Rank
Computational Linguistics
#1905
World Rank
#1925
Historical Rank
Machine Learning
#3498
World Rank
#3541
Historical Rank
Artificial Intelligence
#3802
World Rank
#3857
Historical Rank
Download Badge
Computer Science
Peter Dreger's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Peter Dreger Influential?
(Suggest an Edit or Addition)Peter Dreger's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients (1996) (636)
- Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) (1995) (513)
- Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus (2007) (423)
- Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (2009) (344)
- Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually (2016) (329)
- G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft (1994) (324)
- Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. (2010) (300)
- Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015 (2015) (288)
- Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. (2009) (284)
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. (2010) (248)
- Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. (1995) (234)
- Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. (2012) (229)
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses (2012) (224)
- Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation. (2011) (221)
- Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice (2014) (219)
- Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. (1996) (217)
- Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. (2009) (201)
- The EBMT activity survey: 1990–2010 (2012) (195)
- Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? (2014) (195)
- ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). (2013) (194)
- Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning (2003) (193)
- Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants (2015) (189)
- Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia (2013) (185)
- Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 (2019) (181)
- Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. (2011) (181)
- Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. (2008) (177)
- Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. (2004) (173)
- Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. (2006) (167)
- Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation (2014) (162)
- Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis (2005) (162)
- Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. (1997) (158)
- Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). (2017) (154)
- p53-dependent non-coding RNA networks in chronic lymphocytic leukemia (2015) (140)
- Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia (2002) (135)
- Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. (2003) (134)
- Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation [letter] (1993) (129)
- Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. (2011) (128)
- Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. (2020) (124)
- Hematopoietic SCT in Europe: data and trends in 2011 (2013) (119)
- Generation of Cytotoxic Responses in Mice and Human Individuals Against Hematological Malignancies Using Survivin-RNA-Transfected Dendritic Cells1 (2003) (118)
- GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. (2007) (117)
- The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. (2004) (113)
- Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. (2017) (110)
- Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. (2013) (107)
- Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. (2013) (103)
- TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. (2013) (102)
- Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party (2013) (96)
- Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. (2013) (96)
- Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marr (2012) (95)
- Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. (2014) (95)
- Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial (2008) (90)
- Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation (2004) (90)
- Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. (2006) (88)
- Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. (1993) (85)
- Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (2016) (84)
- Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry (2008) (83)
- G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. (1995) (82)
- Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. (2011) (80)
- Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis (2014) (78)
- Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. (2013) (77)
- Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT (2015) (76)
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, (2010) (76)
- Effects of physical exercise on survival after allogeneic stem cell transplantation (2015) (75)
- Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. (2012) (75)
- PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. (2019) (73)
- High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. (2018) (72)
- Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. (2014) (71)
- Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) (2019) (71)
- Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. (2014) (69)
- Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? (1998) (66)
- Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients (2018) (65)
- Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. (2007) (65)
- The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma (2014) (65)
- Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. (2019) (64)
- EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. (2017) (64)
- Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. (2016) (63)
- Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. (2013) (63)
- Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. (2011) (62)
- Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia (2016) (62)
- Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. (1995) (61)
- Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit (2013) (61)
- Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. (1993) (61)
- Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP (2014) (61)
- ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data (2016) (60)
- Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD (2017) (59)
- Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). (2014) (59)
- Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. (2009) (58)
- Allogeneic peripheral blood progenitor cell transplantation in a murine model : Evidence for an improved graft-versus-leukemia effect (1997) (57)
- Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties (2018) (57)
- Allogeneic MHC‐mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft‐versus‐leukaemia effect in mice (1997) (56)
- Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. (2017) (56)
- Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms. (1993) (56)
- Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. (2017) (55)
- Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. (2018) (55)
- Allogeneic transplantation in lymphoma: current status (2007) (54)
- Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party (2014) (54)
- Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium (2012) (52)
- Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. (2018) (51)
- Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia (2013) (50)
- Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL (1997) (50)
- Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). (2012) (50)
- Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood (2014) (49)
- Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia : long-term clinical and MRD results of the German CLL Study Group CLL 3 X trial (2010) (49)
- Efficacy of exercise training in SCT patients-who benefits most? (2014) (49)
- Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia (1999) (48)
- Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy (1998) (47)
- Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR (2018) (47)
- The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry (2010) (47)
- Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. (2011) (47)
- Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery (1999) (46)
- EASIX and mortality after allogeneic stem cell transplantation (2019) (45)
- Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. (2017) (44)
- The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. (2000) (44)
- Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes (2016) (44)
- Molecular Characterization of a Respiratory Syncytial Virus Outbreak in a Hematology Unit in Heidelberg, Germany (2012) (44)
- Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients (2021) (44)
- Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients (2019) (43)
- Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG). (2004) (43)
- Allotransplantation for chronic lymphocytic leukemia. (2009) (43)
- Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease. (2014) (43)
- Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. (2020) (42)
- Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma (2011) (42)
- No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. (2011) (42)
- Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. (2018) (42)
- Epstein–Barr virus‐associatedpost‐transplant lymphoproliferative disease after bone marrow transplantation mimicking graft‐versus‐host disease (2000) (42)
- Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? (2009) (41)
- Chimeric antigen receptor transduced T cells: Tuning up for the next generation (2018) (40)
- Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation (2017) (40)
- Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party (2016) (40)
- Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT) (2017) (39)
- Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective. (2000) (39)
- Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells (2011) (39)
- Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT (2016) (39)
- Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation (2016) (39)
- Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation (1997) (39)
- The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. (2014) (39)
- Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis (2012) (39)
- Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2016) (38)
- Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation (2017) (38)
- High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. (1996) (38)
- Identification of HLA-A*0201-Presented T Cell Epitopes Derived from the Oncofetal Antigen-Immature Laminin Receptor Protein in Patients with Hematological Malignancies (2006) (37)
- The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? (2005) (36)
- Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party (2018) (35)
- Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. (2021) (35)
- Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. (2001) (35)
- Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice (2014) (34)
- Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT (2019) (34)
- NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic (2010) (33)
- GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. (2022) (32)
- Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study (2015) (32)
- Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect (2004) (32)
- Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. (2006) (32)
- Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients (2020) (31)
- Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation. (2016) (31)
- Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. (2019) (31)
- Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease (2012) (31)
- A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. (2000) (30)
- Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. (1997) (30)
- Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34+ Selection Systems (1997) (30)
- High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation (2015) (30)
- Determinants of exercise adherence and contamination in a randomized controlled trial in cancer patients during and after allogeneic HCT (2016) (30)
- Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. (2018) (30)
- Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. (2001) (30)
- Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL (2020) (29)
- Cell-based immunotherapy approaches for multiple myeloma (2018) (29)
- Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse (2015) (29)
- Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW (2010) (29)
- Comparison of different strategies of molecular genetic monitoring following autologous stem cell transplantation in patients with follicular lymphoma (1998) (28)
- Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial (2008) (28)
- Use of eltrombopag in aplastic anemia in Europe (2019) (27)
- Rituximab maintenance improves survival in male patients with diffuse large B‐cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial (2015) (27)
- Rapid engraftment of peripheral blood progenitor cell grafts purged with B cell-specific monoclonal antibodies and immunomagnetic beads. (1995) (26)
- Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW (2011) (26)
- Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party Of the EBMT. (2016) (26)
- Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes (2004) (25)
- Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation? (2020) (25)
- GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses (2017) (25)
- Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel (2020) (25)
- Centre characteristics and procedure‐related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT) (2017) (25)
- Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (2020) (25)
- Physical Exercise Training versus Relaxation in Allogeneic stem cell transplantation (PETRA Study) – Rationale and design of a randomized trial to evaluate a yearlong exercise intervention on overall survival and side-effects after allogeneic stem cell transplantation (2015) (25)
- Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. (2012) (25)
- Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients (2020) (25)
- IFN-γ activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production. (2010) (25)
- Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group (2013) (24)
- Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (2010) (24)
- Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients (2019) (24)
- Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (24)
- Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation (2021) (24)
- Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience (2017) (24)
- Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies. (2017) (24)
- Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. (2016) (24)
- The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience (2018) (24)
- Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? (2001) (24)
- The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. (2014) (23)
- Alloreactivity: the Janus-face of hematopoietic stem cell transplantation (2017) (23)
- Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT (2000) (23)
- Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma (2014) (23)
- Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma ?: a Retrospective Study From the Lymphoma Working Party of the EBMT (2010) (23)
- Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin’s disease (2004) (23)
- The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma (2012) (22)
- Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia. (2007) (22)
- Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. (2019) (22)
- Exercise intensity classification in cancer patients undergoing allogeneic HCT. (2015) (22)
- Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia. (2017) (22)
- Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. (1997) (21)
- Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review (2014) (21)
- Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party (2018) (21)
- Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL: CLL2H study of the German CLL Study Group (GCLLSG) (2005) (21)
- Epigenetic aging upon allogeneic transplantation: the hematopoietic niche does not affect age-associated DNA methylation (2014) (21)
- EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL) (2019) (21)
- Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis (2011) (21)
- Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease (2005) (20)
- Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol (2019) (20)
- Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation (2015) (20)
- Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors? (2016) (19)
- Elevated blood drug levels obtained from indwelling silicon catheters during oral cyclosporine A administration (2002) (19)
- EASIX for prediction of survival in lower-risk myelodysplastic syndromes (2019) (19)
- Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (2007) (19)
- CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. (2020) (18)
- Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells (2020) (18)
- The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. (2019) (18)
- High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte‐predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation‐lymphoma working party (2018) (18)
- A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. (2020) (18)
- High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party (2018) (18)
- Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience. (2015) (17)
- Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis. (2007) (17)
- Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma (2014) (17)
- Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP‐EBMT study (2020) (17)
- Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT (2015) (17)
- Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation. (2018) (17)
- High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy (2014) (17)
- Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study. (2008) (17)
- Allogeneic peripheral blood progenitor cells: current status and future directions. (1996) (16)
- Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG). (2007) (16)
- Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation. (1998) (16)
- Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells. (2018) (16)
- Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation (2016) (16)
- The evolving role of stem cell transplantation in chronic lymphocytic leukemia. (2013) (16)
- Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers (2008) (15)
- Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party (2018) (15)
- EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients (2021) (15)
- Allogenic transplantation of mobilized peripheral blood progenitor cells: towards tailored cell therapy. (1997) (15)
- Autologous stem cell transplantation for chronic lymphocytic leukemia. (2007) (15)
- Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party (2015) (15)
- Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation (2018) (15)
- Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia. (2021) (15)
- Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. (2020) (15)
- Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (2021) (15)
- Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML (2008) (14)
- Hematopoietic stem cell transplantation in patients with lymphomatoid granulomatosis: a European group for blood and marrow transplantation report. (2013) (14)
- Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis (2019) (14)
- Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation? (2020) (14)
- Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome (2018) (14)
- Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma (2015) (14)
- Can Prognostic Factors Be Used to Direct Therapy in Chronic Lymphocytic Leukemia? (2012) (14)
- Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects (2018) (13)
- Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia? (2015) (13)
- Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in “ultra High-risk” CLL: Final Results from the CLL2O Phase II Study (2014) (13)
- Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study) (2008) (13)
- The role of stem cell transplantation in the treatment of chronic lymphocytic leukemia. (1997) (13)
- Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom’s Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party (2014) (12)
- Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma (2021) (12)
- Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data (2020) (12)
- Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma. (2008) (12)
- The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies (2018) (12)
- Granulocyte‐colony‐stimulating factor induces increased serum levels of soluble interleukin 2 receptors preceding engraftment in autologous bone marrow transplantation (1993) (12)
- Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies (2019) (12)
- Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party (2019) (11)
- Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia (2019) (11)
- The Role of Allogeneic Stem Cell Transplantation in Hodgkin’s Lymphoma (2014) (11)
- Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk-adapted therapy. (1999) (11)
- PBPC grafts from healthy donors: analysis of CD34+ and CD3+ subpopulations. (1996) (11)
- Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects (2012) (11)
- Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia ‐ A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT (2017) (11)
- ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma. (2021) (11)
- Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses (2017) (10)
- Azacitidine and low‐dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts – a retrospective single‐center experience (2014) (10)
- Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome (2015) (10)
- Autologous transplant of follicular lymphoma in the era of rituximab (2010) (10)
- Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas (2016) (10)
- Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR (2020) (10)
- Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis (2019) (10)
- Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation (2010) (9)
- Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation (2019) (9)
- Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT). (1998) (9)
- Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and stem cell factor (SCF) as compared to G-CSF alone. (1998) (9)
- Improved relapse‐free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation‐Intergroup study (2014) (9)
- Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas (2017) (9)
- Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy (2016) (9)
- Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial (2010) (9)
- DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL (2017) (9)
- Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study (2016) (9)
- Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT) (2017) (9)
- The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial (2020) (8)
- Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics (2021) (8)
- Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study (2019) (8)
- Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT (2020) (8)
- High‐dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL‐GITMO (2018) (8)
- B‐cell maturation antigen‐specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives (2020) (8)
- Bone Marrow Harvesting of Allogeneic Donors in an Outpatient Setting: A Single-Center Experience. (2016) (8)
- Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor (2019) (8)
- Rituximab Maintenance Therapy After Autologous Stem Cell Transplantation Prolongs Progression Free Survival In Patients With Mantle Cell Lymphoma (2013) (8)
- High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease (1993) (8)
- Proteogenomics refines the molecular classification of chronic lymphocytic leukemia (2022) (7)
- BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials (2019) (7)
- Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party (2020) (7)
- Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation. (2015) (7)
- FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY (2019) (7)
- Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). (2012) (7)
- Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC (2000) (7)
- Allogeneic Transplantation in Patients with HIV-Infection:A Pair Matched Cohort Study by the European Society forBlood and Marrow Transplantation (2015) (7)
- Amplification of a Y‐chromosomal DNA sequence by the polymerase chain reaction for documentation of residual recipient cells in small samples from bone marrow, peripheral blood and cerebrospinal fluid after bone marrow transplantation (1993) (7)
- Impact of HSCT Conditioning and Glucocorticoid Dose on Exercise Adherence and Response (2017) (7)
- Immunotherapeutic aspects of allogeneic peripheral progenitor cells. (1998) (7)
- CD4+CD25highCD127low Regulatory T Cells in Peripheral Blood Are Not an Independent Factor for Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation (2012) (7)
- Evidence that reduction of immunogenicity of T-depleted bone marrow depends on additional depletion of accessory cells. Implications for prevention of graft rejection. (1990) (7)
- Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT (2016) (7)
- Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party (2017) (7)
- Indications for Hematopoietic Stem Cell Transplantation in Patients with Waldenstrom's Macroglobulinemia: A Consensus Project of the EBMT Lymphoma Working Party (LWP)/ European Consortium for Waldenstrom's Macroglobulinemia (ECWM)/International Waldenstrom's Macroglobulinemia Foundation (IWMF) (2017) (7)
- Improvement of Long-Term Survival after High-Dose Melphalan in Patients with Light Chain Amyloidosis Responding to Induction Chemotherapy. (2008) (7)
- Allogeneic transplantation of peripheral blood stem cells. (1999) (7)
- What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion? (2013) (7)
- Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy (2021) (7)
- Early Autologous Stem Cell Transplantation (SCT) in Genetically Poor-Risk Chronic Lymphocytic Leukemia Is Feasible and Effective: Results from a Prospective Multicenter Study (GCLLSG CLL3 Protocol). (2004) (6)
- Stem Cell Mobilization in Healthy Donors: Current Status (1999) (6)
- High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group. (2012) (6)
- Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation (2019) (6)
- Precast commercial polyacrylamide gels for separation of DNA amplificates by temperature gradient gel electrophoresis: Application to clonality analysis of lymphomas (1996) (6)
- Erratum: Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice (Bone Marrow Transplantatio (2014) 49 (319) DOI:10.1038/bmt.2013.210) (2014) (6)
- Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT (2019) (6)
- Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial (2022) (6)
- Epstein-Barr virus-associated post-transplant lymphoproliferative disease after bone marrow transplantation mimicking graft-versus-host disease. (2000) (6)
- Early bilirubinemia after allogeneic stem cell transplantation—an endothelial complication (2021) (6)
- Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning (2019) (6)
- Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO) (2014) (6)
- The Epstein–Barr virus DNA load in the peripheral blood of transplant recipients does not accurately reflect the burden of infected cells (2017) (6)
- EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study (2022) (6)
- Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior to transplantation (2020) (6)
- Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan/Fludarabine to Reduced Intensity Conditioning with Busulfan/Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplasti (2017) (6)
- A prospective study on serum Cytokeratin (CK)-18 and CK18 fragments as biomarkers of acute hepato-intestinal GVHD (2018) (6)
- American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma (2021) (6)
- Minimal Residual Disease (MRD) Kinetics after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Correlate to IgH VH Mutational Status and Predict Post Transplant Outcome: Real Time ASO-IgH PCR Results of the GCLLSG CLL3 Protocol. (2004) (6)
- Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial (2016) (6)
- Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD (2021) (5)
- Influence of G-CSF on NK cell recovery after autologous BMT. (1994) (5)
- Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study. (2009) (5)
- Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation (2018) (5)
- Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis (2011) (5)
- Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT (2020) (5)
- Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation (2018) (5)
- An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission (2011) (5)
- Risk stratification of mantle cell lymphoma (MCL) (2018) (5)
- Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells. (2021) (5)
- Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia (2016) (5)
- Haplotransplants Versus Other Alternative Donors for Allogeneic Stem Cell Transplantation in Non Hodgkin Lymphoma (NHL): A Retrospective Analysis of the EBMT Lymphoma Working Party (2014) (5)
- CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease (2020) (5)
- Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells (2020) (5)
- Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a “graft-versus-plasma cell-dyscrasia effect” (2009) (5)
- GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses (2017) (5)
- Survival and Freedom from Progression in Autotransplant Lymphoma Patients is Independent of Stem Cell Source: Further Follow-up from the Original Randomised Study to Assess Engraftment (2002) (5)
- Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model (2003) (5)
- Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease (2021) (5)
- Fatal late onset CAR T cell-mediated encephalitis after axicabtagene ciloleucel in a patient with large B-cell lymphoma. (2021) (5)
- Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation (2022) (5)
- Transplant Outcome of Unrelated Hematopoietic Stem Cell Transplantation (HSCT) after Myelo-Ablative or Reduced Intensity Conditioning (RIC) for Chronic Lymphocytic Leukemia(CLL). A Study of EBMT Registry. (2005) (4)
- A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (2019) (4)
- Impact of Graft-Versus-Host Disease On Relapse After Allogeneic Hematopoietic Stem Cell Transplantation, an EBMT Megafile Study (2012) (4)
- A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) (4)
- Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study (2014) (4)
- Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: Ready for primetime? (2009) (4)
- Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. (2022) (4)
- Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial (2021) (4)
- Spontaneous lymphoblastoid cell lines from patients with Epstein-Barr virus infection show highly variable proliferation characteristics that correlate with the expression levels of viral microRNAs (2019) (4)
- Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo (2018) (4)
- Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma. (2009) (4)
- An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies (2021) (4)
- Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial) (2018) (4)
- Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (2019) (4)
- Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies (2018) (4)
- Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma (2018) (4)
- Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation (2020) (4)
- Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch. (2009) (4)
- Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia (2019) (4)
- Treatment-Related MDS/AML after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL): An EBMT Survey. (2005) (4)
- Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin lymphoma - Interim results of a multicenter prospective randomised phase II study. (2006) (4)
- Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study (2022) (4)
- CD7 is expressed on a subset of normal CD34‐positive myeloid precursors (2018) (4)
- Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT (2018) (4)
- Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia (2022) (4)
- Metabolic syndrome is common following haematopoietic cell transplantation (HCT) and is associated with increased cardiovascular disease: an EBMT cross-sectional non-interventional study (2015) (4)
- The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis (2020) (4)
- leukemia: ready for prime time? Allogeneic hematopoietic cell transplantation for chronic lymphocytic (2009) (4)
- High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience (2020) (4)
- Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents (2019) (3)
- S282: A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA FROM CONVALESCENT AND VACCINATED DONORS IMPROVES OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASE, CANCER OR IMMUNOSUPPRESSION (2022) (3)
- Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial (2022) (3)
- Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH) (2015) (3)
- Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin’s Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2014) (3)
- Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study (2018) (3)
- Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial. (2009) (3)
- Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation (2009) (3)
- It Is Easix to Predict Non-Relapse Mortality (NRM) of Allogeneic Stem Cell Transplantation (alloSCT) (2016) (3)
- In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia (2014) (3)
- IFN-gamma activated JAK-1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production (2018) (3)
- Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study, (2011) (3)
- Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy (2018) (3)
- Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers (2014) (3)
- Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party (2014) (3)
- The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells (2019) (3)
- Secondary Malignancies After Autologous Stem Cell Transplantation In Patients With Relapsed / Refractory Hodgkin´s Lymphoma. A Retrospective Analysis On Behalf Of The Lymphoma Working Party Of The European Society For Blood and Marrow Transplantation (EBMT) (2013) (3)
- The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT) (2016) (3)
- Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT (2014) (3)
- Outcome and Prognostic Factors in Patients with Mantle Cell Lymphoma Relapsing After Autologous Stem Cell Transplantation: A Retrospective Study of the EBMT (2012) (3)
- Comments on “Cost of decentralized CAR T cell production in an academic non‐profit setting” (2020) (3)
- Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study (2021) (3)
- Remission Status at Transplantation and Treatment History Determine the Survival Chances of Patients after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia Who Had Received Pre-Treatment with Idelalisib: A Report from the EBMT Chronic Malignancies Working Party (2017) (3)
- Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey (2020) (3)
- Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia – a study of the Acute Leukemia Working Party of the EBMT (2020) (3)
- Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party (2016) (3)
- Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease (2018) (3)
- Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling (2022) (3)
- In vivo T-cell depletion in allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: a retrospective EBMT analysis (2009) (3)
- Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up (2013) (2)
- The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis (2019) (2)
- Evaluation of Safety and Efficacy of Different Stem Cell Mobilization Regimens in 110 Patients with Light Chain Amyloidosis (2008) (2)
- Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation (2019) (2)
- for chronic lymphocytic leukemia containing conditioning regimen and autologous stem cell transplantation Autologous graft versus host disease-like syndrome after an alemtuzumab (2013) (2)
- T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective EBMT Analysis. (2009) (2)
- Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients (2022) (2)
- MRD Kinetics Can Predict the Time to Relapse after Autologous Stem Cell Transplantation (SCT) in Chronic Lymphocytic Leukemia (CLL). (2005) (2)
- Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL (2022) (2)
- Transplantation in CLL: what we can learn from a dinosaur (2016) (2)
- Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP) (2020) (2)
- Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor‐risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial (2017) (2)
- Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens (2019) (2)
- Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis. (2018) (2)
- High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study (2014) (2)
- High-Dose Therapy and Autologous Stem Cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for Blood and Marrow Transplantation (EBMT). (2012) (2)
- Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL): An analysis based on EBMT registry. (2007) (2)
- Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects (2020) (2)
- Transplantation strategies in chronic lymphocytic leukemia: current concepts of the German CLL Study Group and the EBMT. (2004) (2)
- Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial) (2010) (2)
- Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study (2021) (2)
- The EBMT Lymphoma Working Party-European Mantle Cell Lymphoma Network Consensus Project On The Role Of Autologous and Allogeneic Stem Cell Transplantation In Mantle Cell Lymphoma: Recommendations Applying The Delphi Procedure (2013) (2)
- Quantitative Assessment of Molecular Remission Following Autologous Stem Cell Transplantation Predicts Long Term Remission in Mantle Cell Lymphoma. (2005) (2)
- Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. (2022) (2)
- Extracorporeal Photopheresis for Steroid-refractory Chronic Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis (2015) (2)
- High VEGF Serum Levels on Days +50 and +100 after Allogeneic Stem Cell Transplantation Predict Severe Chronic GvHD (2014) (2)
- A CD48 monoclonal antibody for reduction of graft immunogenicity. (1990) (2)
- Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP) (2008) (2)
- Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study (2021) (2)
- Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis (2015) (2)
- Allogeneic stem cell transplant in non‐Hodgkin lymphomas: Still an indication? (2021) (2)
- Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from the European Society for Blood and Marrow Transplantation (EBMT (2014) (2)
- Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study (2020) (2)
- III. Role of allotransplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia (2011) (2)
- Imatinib‐supplemented myeloablative total‐body irradiation/cyclophosphamide conditioning prior to allogeneic stem cell transplantation as consolidation treatment in patients with blast crisis of chronic myeloid leukemia (2014) (2)
- Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation (2022) (2)
- Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL) (2020) (2)
- Safety and Efficacy of Idelalisib Treatment of Chronic Lymphocytic Leukemia (CLL) or Lymphoma Relapsing after Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Survey By the EBMT Chronic Malignancies and Lymphoma Working Parties (2017) (2)
- Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma (2016) (2)
- High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial (2013) (1)
- Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2016) (1)
- Autologous Stem Cell Transplantation For Adult Burkitt Lymphoma In The Rituximab Era: A Retrospective Study Of The Lymphoma Working Party (LWP) Of The European Group For Blood and Marrow Transplantation (EBMT) (2013) (1)
- IgM-Gammopathie - Differenzialdiagnose, Klinik und Therapie (2007) (1)
- Analysis of the contemporary use of high-dose chemotherapy (HDCT) in germ cell tumors (GCT) in Europe: Early findings of an ongoing EBMT-sponsored study. (2014) (1)
- Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma. (2006) (1)
- Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile (2020) (1)
- Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial (2022) (1)
- ATG and Statins Reduce Incidence of Severe Chronic Gvhd By Distinct Mechanisms Involving CXCL9 and Kynurenine Catabolism (2015) (1)
- Depletion of accessory cells strongly reduces immunogenicity of T-depleted bone marrow, and thus may facilitate its engraftment. (1989) (1)
- Combinatorial drug-microenvironment interaction mapping reveals cell-extrinsic drug resistance mechanisms and clinically relevant patient subgroups in CLL (2021) (1)
- Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies. (2007) (1)
- Matched Unrelated Donor Transplantation Is Curative In Selected Patients with Diffuse Large B Cell Lymphoma: A Report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) (2010) (1)
- Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT (2019) (1)
- The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party (2011) (1)
- Allogeneic stem cell transplantation for patients with resistant high-grade lymphoma: what is the potential of reduced-intensity conditioning? (2002) (1)
- Evaluation of minimal residual disease in chronic lymphocytic leukemia (2009) (1)
- SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial (2012) (1)
- Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia (2022) (1)
- Favorable Influence of Pretransplant Rituximab but Not of High-Dose Ara-C in Upfront Autologous Stem Cell Transplantation (SCT) for Mantle Cell Lymphoma (MCL). (2005) (1)
- Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. (2012) (1)
- Allogeneic Stem Cell Transplantation for Hodgkin's Disease From Sibling and Unrelated Donors: The German Cooperative Transplantation Study Group Experience. (2009) (1)
- 860PIMPACT OF RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH GERM CELL TUMORS (GCT) RECEIVING SALVAGE HIGH-DOSE CHEMOTHERAPY (HDCT): A STUDY OF THE EBMT SOLID TUMORS WORKING PARTY (STWP). (2014) (1)
- Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia? (2021) (1)
- Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative Donor (2016) (1)
- Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience (2022) (1)
- Imaging-based coculture model for high-throughput compound screening in hematological cancers (2022) (1)
- Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: The EBMT experience. (2016) (1)
- Unrelated Donor Reduced-Intensity Stem Cell Transplantation Is A Promising Treatment Option For Elderly Patients With Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDC) (2010) (1)
- Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma - First Interim Results of a Prospective Randomised Phase II Study. (2005) (1)
- Monoclonal IgM Gammopathy - Differential Diagnosis, Clinical Presentation, and Therapy (2007) (1)
- Reduced Intensity Allogeneic Stem Cell Transplantation For Follicular Lymphoma Relapsing After An Autologous Transplantation. An Analysis From The EBMT (2013) (1)
- Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) From Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). A Long-Term Follow-Up (10 Years) Study From the EBMT Registry (2009) (1)
- Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters (2022) (1)
- Autografting and Allografting for Chronic Lymphocytic Leukemia: Is there a Rationale? (2003) (1)
- Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible After Solid Organ Transplantation: A Retrospective Analysis By The Early Complications Subcommittee Of The Complications and Quality Of Life Working Party, EBMT (2013) (1)
- Mapping drug-microenvironment-genetic interplay in CLL reveals trisomy 12 as a modulator of microenvironmental signals (2021) (1)
- CD48 monoclonal antibody K31 for bone marrow transplantation. (1992) (1)
- Statin‐based endothelial prophylaxis and outcome after allogeneic stem cell transplantation (2022) (1)
- Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis (2021) (1)
- No Major Complications In Children After Stem Cell Donation At One Year Follow-Up: EBMT Pediatric Diseases Working Party Study (2013) (1)
- Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin lymphoma - Interim results of a multicenter prospective randomised phase II study (2006) (1)
- Complementary JAK/STAT Signalling Is Required for the Pro-Inflammatory Effects of CD40 Ligation: Differential Effects in Human Myeloid and B Cells. (2007) (1)
- Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial) (2014) (1)
- Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia - Still a Valid Treatment Option, or is the Game Over? (2012) (1)
- DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT‐LWP STUDY (2019) (1)
- No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy (2018) (1)
- Pre-transplant testosterone and outcome of men after allogeneic stem cell transplantation (2019) (1)
- The Second Signal in Antigen-Presenting Cells: Complementary JAK1/JAK2 and CD40 Signalling Mediate Pro-Inflammatory Activation. (2008) (1)
- Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial (2022) (1)
- [Chronic lymphatic leukemia. Current therapy concepts]. (2002) (1)
- Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation (2020) (1)
- Stem Cell Transplantation: The Basis for Successful Cellular Immunotherapy (2006) (1)
- P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY (2022) (1)
- Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy (2021) (1)
- Real-World Results of CAR-T Cell Therapy for Large B Cell Lymphoma with CNS Involvement: A GLA/DRST Study (2022) (1)
- Graft Versus Host Disease-Like Syndrome after Autologous Stem Cell Transplantation in CLL Patients Treated with a TBI/Cy/Alemtuzumab (CAMPATH-1H) High-Dose Regimen. (2005) (1)
- Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL) (2018) (1)
- Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) (2015) (1)
- Cell-based immunotherapy approaches for multiple myeloma (2018) (1)
- HUMAN LEUKOCYTE ANTIGEN MATCHING AND CONDITIONING IMPACT ON LONG-TERM TRANSPLANT OUTCOME AFTER ALLOGENEIC HSCT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (2010) (1)
- Peripheral blood progenitor cell but not bone marrow grafts are affected by previous Dexa-BEAM chemotherapy (1994) (1)
- A Phase IIIb Study of Rituximab Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy - MAXIMA-Protocol. (2006) (1)
- Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy (2021) (1)
- CD48 monoclonal antibody K31 for bone marrow transplantation: T-depleting capacity and influence on hematopoietic progenitors. (1993) (1)
- Outcome Of Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma (ATL) Who Have Undergone Stem Cell Transplantation: A Retrospective Study Of The EBMT Lymphoma Working Party (2013) (1)
- OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS (2021) (1)
- Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis (2021) (1)
- Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2016) (1)
- Comment to “The outcome of peripheral T-cell lymphoma patients failing first-line therapy” (2019) (1)
- Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT (2020) (1)
- Haploidentical versus matched unrelated donor transplants using post-transplant cyclophosphamide for lymphomas. (2022) (1)
- Allogeneic transplantation of blood stem cells: Coming of age? (2001) (1)
- Graft versus leukemia effect may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status. (2004) (1)
- Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial (2019) (1)
- Immunogenetic Donor Selection Criteria in Allogeneic Stem Cell Transplantation (2014) (0)
- The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers (2018) (0)
- Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study (2023) (0)
- Outbreak of Nosocomial Respiratory Syncytial Virus Infections in a Hematology and Transplant Unit. (2012) (0)
- Donor Selection for Allogeneic Hematopoietic Cell Transplantation. (2023) (0)
- Corrigendum: GvL effects in T-prolymphocytic leukemia (2017) (0)
- 5.8 Fludarabine-Cyclophosphamide-Rituximab vs Autologous Stem Cell Transplantation as First-Line Treatment for CLL: A Comparison of 2 Prospective Studies of the GCLLSG (2011) (0)
- ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS (2021) (0)
- transplantation for chronic lymphocytic leukemia cell alemtuzumab-containing conditioning regimen and autologous stem like syndrome after an - Autologous graft-versus-host disease (2012) (0)
- Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT (2013) (0)
- Chronic Lymphocytic Leukemia (2018) (0)
- Low Pre-Transplant Levels of 25-Hydroxyvitamin D3 Predict Relapse and Survival in Male but Not in Female Patients Undergoing Allogeneic Stem Cell Transplantation (2014) (0)
- Donor EBV status has impact on the incidence of acute and chronic GVHD (2015) (0)
- High Pre-Transplant Free Interleukin-18 Is Associated with Poor Hematopoietic Recovery after Allogeneic Stem Cell Transplantation (2019) (0)
- Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party (2012) (0)
- Title Page / Table of Contents (2009) (0)
- It is Easix to Predict Mortality of Low Risk MDS Patients (2017) (0)
- Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2023) (0)
- Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells (2016) (0)
- Acknowledgement 2002 (2003) (0)
- Serum Asymmetric Dimethylarginine (ADMA) Levels Predict Steroid-Refractory Gvhd before Allogeneic Stem Cell Transplantion (2014) (0)
- Response to Vaccination with Sars-CoV2 Vaccines in Patients Post Allogeneic Hematopoietic Cell Transplantation (2022) (0)
- Impact of Resistance Exercise and Nutritional Endorsement on physical performance in patients with GvHD (IRENE-G study) – design and rational of a randomized controlled trial (2022) (0)
- Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning Regimen (2015) (0)
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS FEASIBLE AFTER SOLID ORGAN TRANSPLANTATION: FINAL ANALYSIS BY THE EARLY COMPLICATIONS SUBCOMMITTEE OF THE COMPLICATIONS AND QUALITY OF LIFE WORKING PARTY, EBMT (2014) (0)
- High Impact of Human Leukocyte Antigen Matching On Overall Survival and Transplant Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Long-Term Study From the EBMT Registry. (2009) (0)
- Reply to C. Fozza. (2013) (0)
- Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation (2021) (0)
- Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT (2022) (0)
- Chronic Lymphocytic Leukaemia (2022) (0)
- Quality of Life in Patients with B-Cell Lymphoma during Maintenance Therapy with the Anti-CD20 Antibody Rituximab. (2007) (0)
- Working Parties (1991) (0)
- Physical Exercise Training versus Relaxation in Allogeneic stem cell transplantation (PETRA Study) – Rationale and design of a randomized trial to evaluate a yearlong exercise intervention on overall survival and side-effects after allogeneic stem cell transplantation (2015) (0)
- Comparative analysis of minimal residual disease by 4 color flow cytometry (4CFC) and quantitative IgH PCR (RQ-PCR) in chronic lymphocytic leukemia (CLL) after stem cell transplantation (SCT) (2004) (0)
- Cancer Therapy : Preclinical Le fl unomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells (2012) (0)
- Survivin-RNA-Transfected Dendritic Cells Hematological Malignancies Using and Human Individuals Against Generation of Cytotoxic Responses in Mice (2003) (0)
- Very early detection of donor cells after BMT in the blood, the oral cavity, and urinary tract by PCR (1994) (0)
- Favourable Outcome after Treosulfan Based Conditioning of Patients Receiving an Allogeneic Hematopoietic Cell Transplantation (AlloHCT) for the Treatment of a Myelodysplastic Syndrome (MDS) (2022) (0)
- Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). (2022) (0)
- Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation (2022) (0)
- Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study (2021) (0)
- dendritic cells GSK-3 mediates differentiation and activation of proinflammatory (2013) (0)
- Comparison of outcomes after unrelated cord blood transplantation and matched unrelated donor reduced-intensity conditioning regimen transplantation for lymphoid malignancies - a Eurocord-Netcord Group/LWP and CLWP of the EBMT Study (2010) (0)
- Drug-microenvironment-genetic interplay in CLL 5 6 (2021) (0)
- Female Donors Are Associated with an Increased Risk of Chronic Graft-Versus-Host Disease (cGVHD) Independent of Recipient Sex but Provide Superior Graft-Versus-Leukemia Activity Once cGVHD Is Established (2014) (0)
- Pentostatin for First-Line Salvage Therapy of Steroid-Refractory Intestinal Acute Graft-Versus-Host Disease; a Dual Center Retrospective Analysis (2010) (0)
- Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2017) (0)
- Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL) (2014) (0)
- Chronische lymphatische Leukämie Aktuelle Therapiekonzepte (2014) (0)
- A Study on the Prognosis of Patients Relapsing after Autologous Stem Cell Transplantation (auto-SCT) for Follicular Lymphoma (FL): The Impact of Remission Duration. (2006) (0)
- Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST) (2021) (0)
- Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation (2022) (0)
- Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data (2019) (0)
- Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL) (2007) (0)
- Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial (2014) (0)
- Acknowledgement to Reviewers (2013) (0)
- Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation (2022) (0)
- Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation (2021) (0)
- Peripheral Blood Progenitor Grafts Obtained from Healthy Donors (1997) (0)
- Pre-Transplant Weight Loss and Total Serum Protein Predict Relapse Of Acute Myeloid Leukaemia After Allogeneic Stem Cell Transplantation (2013) (0)
- Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party (2013) (0)
- CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL) (2022) (0)
- Treatment of High Risk AML and MDS with Ara-C-Containing Standard Chemotherapy Followed by Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC-SCT) during Aplasia: A Survey of the German Cooperative Transplant Study Group (GCTSG). (2006) (0)
- T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses (2015) (0)
- Impact of drug development on the use of stem cell transplantation. A report by the activity survey of the European Society for Blood and Marrow Transplantatio (EBMT) (2016) (0)
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO‐HSCT) FOR PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (R/R SALCL). A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING PARTY‐EBMT. (2017) (0)
- Expression of CDKN1C/p57KIP2 predict loss of proliferative phenotype in CD34+cells and poor prognosis of MDS patients (2013) (0)
- Haploidentical Versus Matched Unrelated Donor Transplants for Lymphomas Using Post-Transplant Cyclophosphamide: A Joint CIBMTR/EBMT Study (2022) (0)
- Elimination of minimal residual disease in chronic lymphocytic leukemia using allogeneic stem cell transplantation (2009) (0)
- The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients (2019) (0)
- The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organizing Committee (2019) (0)
- P1198: ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AND CLINICAL OUTCOMES FOLLOWING SECOND-LINE AXICABTAGENE CILOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (2022) (0)
- Salvage brentuximab vedotin prior to allogeneic hematopoietic cell transplantation in classical hodgkin lymphoma does not impact survival but reduces the incidence of chronic GVHD: a retrospective study of the EBMT Lymphoma Working Party. (2017) (0)
- 8 Gy TBI/cyclophosphamide (TBI8/CY) as conditioning regimen for allogeneic transplantation in patients with advanced multiple myeloma. (2014) (0)
- Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT (2018) (0)
- Pretransplant NPM1 -MRD Levels Predict Outcome after Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia (2015) (0)
- Enrichment of G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation by negative selection. (1994) (0)
- Interleukin-12 and Interleukin-18 Associate with Chronic Graft-Versus-Host Disease but with Inverse Clinical Outcomes (2022) (0)
- Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. (2016) (0)
- Infusion-related side-effects in children undergoing autologous hematopoietic stem for (2000) (0)
- TKI discontinuation after allogeneic stem cell transplantation in patients with chronic myeloid leukemia (CML): A retrospective study from the chronic malignances working party (CMWP) (2019) (0)
- Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience (2015) (0)
- Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party (2018) (0)
- Response Signature to the CD95-Ligand Inhibitor Asunercept Involve Low Serum P53 and Rankl (2017) (0)
- Long-term survival of patients with MDS after allogeneic transplantation : a report from the Chronic Malignancies Working Party of EBMT (2017) (0)
- Conditioning for Allogeneic Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma: Less is More (2021) (0)
- Influence of inflammatory bowel disease on the outcome of allogeneic stem cell transplantation: A matched-pair analysis study from the transplant complications working party of EBMT (2019) (0)
- Human leukocyte antigen matching and conditioning Impact on long-term transplant outcome after allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia : study from the EBMT Registry (2010) (0)
- High Progression-Free Survival after TBI-Containing Reduced Intensity Conditioning in Patients with Chronic Myelomonocytic Leukemia (2017) (0)
- A Multicenter Retrospective Analysis on Pentostatin As Salvage Therapy of Severe Steroid Refractory Intestinal Acute Graft Versus Host Disease (2011) (0)
- P-105 Loss of proliferative phenotype and expression of CDKN1C/p57KIP2 in CD34+ cells predict poor prognosis of MDS (2013) (0)
- Patient-Reported Outcomes (PROs) in Zuma-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL) (2022) (0)
- Leflunomide Overcomes CD40L/IL-4-Mediated Resistance to Fludarabine-Induced Apoptosis and Effectively Blocks Proliferation of CLL Cells (2010) (0)
- Easix for Prediction of Survival in Myelodysplastic Syndromes (2019) (0)
- Non Interventional Prospective Clinical Study on Peripheral Blood Stem Cell Mobilization in Patients with Relapsed Lymphomas (2014) (0)
- Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation (2022) (0)
- Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT) (2016) (0)
- Acknowledgement to referees (2020) (0)
- Rituximab Maintenenance Therapy Prolongs Event Free Survival in Patients with CD20+ B-Cell Non-Hodgkin-Lymphoma. (2007) (0)
- Single Nucleotide Polymorphisms Within The Thrombomodulin Gene (THBD) Predict Risk Of Non-Relapse Mortality In Patients With Graft-Versus-Host Disease (2013) (0)
- Clearance of Minimal Residual Disease (MRD) in patients with 17p-CLL after Allogeneic HCT : Results of the Non-interventional Study of EBMT & ERIC (2015) (0)
- HOW TO SELECT DONOR, STEM CELL SOURCE, AND CONDITIONING REGIMEN FOR HAPLOIDENTICAL TRANSPLANTS WITH POST‐TRANSPLANT CYCLOPHOSPHAMIDE FOR LYMPHOMA: A REPORT OF THE EBMT LWP (2019) (0)
- High Impact Of Human Leukocyte Antigen Matching On Overall Survival And Transplant Related Mortality In Allogeneic Hematopoietic Stem Cell Transplantation For CLL: Long-Term Study From The EBMT Registry (2010) (0)
- Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation: Mediators for Gvl Effects? (2008) (0)
- BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG (2021) (0)
- Low Vitamin D Levels Are Associated with Inferior Survival Following Azacitidine Treatment in Patients with Myelodysplastic Syndrome (2015) (0)
- Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party (2022) (0)
- EBMT Prospective Non-Interventional Study On Allogeneic Hematopoietic Stem Cell Transplantation In T-Prolymphocytic Leukemia (T-PLL). Preliminary Analysis Of 43 Patients (2013) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party (2022) (0)
- Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia (2022) (0)
- Identification of baseline characteristics that predict good outcome of alloSCT in young Cll patients - a retrospective analysis from the CMWP of EBMT (2016) (0)
- HSCT for chronic lymphocytic leukaemia in adults (2008) (0)
- Outcome after autologous stem cell transplantation for myeloma in patients beyond 60, 65 and 70 years of age: A retrospective Analysis from the German Registry for Stem Cell Transplantation (DRST) (2015) (0)
- Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT (2022) (0)
- The Proliferation Inhibitor CDKN1C (P57KIP2) Is Over Expressed in CD34+ Cells of Patients with MDS and Determines a Worse Prognosis Independently of IPSS Score Factors (2012) (0)
- Transplant-Associated Renal Microangiopathy Is Associated with a High Risk of Refractory Gvhd and Characterized By a Specific Biomarker Signature (2014) (0)
- Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study. (2007) (0)
- Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies (2021) (0)
- results of the German CLL Study Group CLL3X trial poor-risk chronic lymphocytic leukemia: long-term clinical and MRD Allogeneic stem cell transplantation provides durable disease control in (2011) (0)
- Allogeneic HSCT in patients with 17p-CLL (2013) (0)
- Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy (2019) (0)
- Genetic Risk of Severe Chronic Graft-Versus-Host Disease Defined By Host-Derived CXCR3 Ligands (2018) (0)
- Contributing and Terminating Factors of a Large RSV Outbreak in an Adult Hematology and Transplant Unit (2014) (0)
- Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany (2022) (0)
- PB2270: CLEARANCE OF PERSISTENT SARS-COV2 INFECTION WITH ANTIBODY CONTAINING PLASMA IN LEUKEMIA AND LYMPHOMA PATIENTS (2022) (0)
- Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL) : Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). (2012) (0)
- Patients with Hematological Malignancies Antigen-Immature Laminin Receptor Protein Cell Epitopes Derived from the Oncofetal Identification of HLA-A * 0201-Presented T (2006) (0)
- Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party (2021) (0)
- Europe-wide survey on the use of thrombopoietin agonists for the treatment of aplastic anemia (2018) (0)
- P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION (2022) (0)
- Current strategies for the diagnosis and management of chronic lymphocytic leukemia (CLL), with a focus on poor-risk CLL: A review. (2011) (0)
- Impact of Resistance Exercise and Nutritional Endorsement on physical performance in patients with GvHD (IRENE-G study) – design and rational of a randomized controlled trial (2022) (0)
- Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD) (2021) (0)
- Allogeneic HCT in Patients with 17p-CLL: Results of a Non-Interventional Study of the EBMT & Eric (2014) (0)
- The Second Signal in Antigen-Presenting Cells: Complementary JAK-1 Directs Pro- and Anti-Inflammatory Cytokine Production Induced by CD40L. (2009) (0)
- IMPROVED RESULTS OF MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) VS REDUCED INTENSITY ALLO-SCT IN MULTIPLY RELAPSED HODGKIN'S LYMPHOMA (HL) IN RECENT YEARS. AN ANALYSIS ON BEHALF OF THE LWP OF THE EBMT (2014) (0)
- Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis (2022) (0)
- BTK, BCL2 or PI3K inhibitors combined with allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia (2017) (0)
- Autologous and Allogeneic Stem Cell Transplantation for Richter's Transformation: A Retrospective Analysis From the Chronic Leukaemia Working Party and Lymphoma Working Party of the EBMT. (2009) (0)
- PF545 EASIX FOR PREDICTION OF SURVIVAL IN LOWER RISK MYELODYSPLASTIC SYNDROMES (2019) (0)
- UPDATED EUROPEAN EXPERIENCE ON AUTOLOGOUS STEM CELL TRANSPLANTATION FOR WALDENSTROM'S MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA PATIENTS. A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY (2014) (0)
- 5.51 Is Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) in CLL Still Under Debate? A Population Matched Analysis Between Auto-HSCT and Rituximab-Fludarabine-Cyclophosphamide in First-Line CLL Patients (2011) (0)
- Allogeneic hematopoietic stem cell transplantation using HLA-compatible donors in younger high cytogenetic risk CLL patients results in very high long-term progression-free survival and may therefore favorably compete with sequential targeted therapy (2017) (0)
- Lenalidomide and rituximab in combination with donor lymphocyte infusions show high efficacy in a patient with early relapse of chronic lymphocytic leukaemia after allogeneic stem cell transplantation (2011) (0)
- ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data. (2016) (0)
- SUN-PO077: Patients Undergoing Allogenic Stem Cell Transplantation Suffer from Poor Nutritional State Despite Supplementation (2019) (0)
- BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY (2017) (0)
- Peripheral Blood Stem Cells for Allogeneic Transplantation (2000) (0)
- Reduction of graft immunogenicity: a new perspective for preventing rejection of T-depleted grafts in a transplantation model. (1987) (0)
- Distinct phenotype of CD19-specific CAR T cells generated from healthy donor vs. patient lymphocytes using either IL-7/IL-15 or IL-2 (2017) (0)
- Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study (2021) (0)
- High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year Follow-up Experience. (2008) (0)
- Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial (2018) (0)
- HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMATOID GRANULOMATOSIS: A SURVEY OF THE LYMPHOMA WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT) (2011) (0)
- Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile (2020) (0)
- T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells (2016) (0)
- Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD (2021) (0)
- Reapplication of High-Dose Chemotherapy with Melphalan Followed by Autologous Hematopoietic Stem Cell Transplantation as Salvage Therapy for Patients with Relapsed Multiple Myeloma (2010) (0)
- High CD34+ cell yields and low rate of secondary MDS/AML using intensive mobilisation for early autologous stem cell transplantation in genetically poor-risk CLL: results from a prospective multicentre study (GCLLSG CLL3 protocol) (2005) (0)
- Kynurenine Pathway Activation and Deviation in Fibrosing Chronic Graft-Versus-Host Disease (2021) (0)
- Upfront Autologous Stem Cell Transplantation (SCT) Ameliorates the Prognostic Disadvantage of an Intermediate/High-Risk FLIPI Score in Patients with Advanced Follicular Lymphoma (FL): Evidence from Two Independent Data Sets. (2005) (0)
- Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey (2021) (0)
- Hematopoietic stem cell transplantation in patients with Lymphomatoid Granulomatosis (LG): A survey of the lymphoma working party of the European Group for Blood and Marrow Transplantation (EBMT) (2012) (0)
- Pre-Transplant Weight Loss Influences Outcome of Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation (2014) (0)
- 166: Quantitative MRD Monitoring Identifies Distinct GVL Response Patterns after Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial (2008) (0)
- Abstract 5557: Systematic mapping of drug sensitivity in hematological malignancies identifies vulnerability of chronic lymphocytic leukemia with mutant p53 (2014) (0)
- Clinical Study CD 4 + CD 25 highCD 127 low Regulatory T Cells in Peripheral Blood Are Not an Independent Factor for Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation (2014) (0)
- Influence of Donor Type, Stem Cell Source and Conditioning Regimen on Transplant Outcomes after Haploidentical Transplant with Post Transplant Cyclophosphamide for Lymphoma: A Report of the EBMT Lymphoma Working Party (2018) (0)
- Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis, (2011) (0)
- The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001- O009) (2021) (0)
- Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction (2019) (0)
- Band 26, Supplement 2, November 1999 (1999) (0)
- Prediction of Chronic Lung Graft-Versus-Host Disease By Angiopoietin-2 (2014) (0)
- P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS (2022) (0)
- Physical performance in hematological cancer patients prior to allogeneic stem cell transplantation (2018) (0)
- Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age (2012) (0)
- Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular iymphoma (2018) (0)
- Drug-microenvironment-genetic interactions in CLL 5 6 (2021) (0)
- Title Pages / Table of Contents (2012) (0)
- Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT (2022) (0)
- Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys (2022) (0)
- Endothelial Stress in Steroid-Refractory Gvhd: A Burden Statins Cannot Lift (2011) (0)
- Eltrombopag for the Treatment of Aplastic Anemia in Europe (2018) (0)
- Mutation analysis by targeted next generation sequencing in ultra high risk CLL patients treated within the CLL20 study (2016) (0)
- MINIMUM TOLERABLE INTERVAL OF (90)YTTRIUM IBRITUMOMAB-TIUXETAN TO AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER HIGH-DOSE CHEMOTHERAPY WITH CARMUSTIN, ETOPOSIDE, CYTARABINE, MELPHALAN IS 10 DAYS. FIRST RESULTS FROM DSHNHL ESC Z-BEAM TRIAL FOR RELAPSED OR REFRACTORY AGGRESSIVE B-NHL (2011) (0)
- The behaviour of WWER nuclear power stations under abnormal operational conditions (1985) (0)
- Allogeneic HSCT in patients with 17p-CLL : first results of a non-interventional prospective study (2013) (0)
- The Outcome of Transplant Strategies for Diffuse Large B Cell Lymphoma in the Last Decade. the EBMT Experience (2012) (0)
- Behaviour of Conjunctival Goblet Cells after allogenic Hematopoietic Stem Cell Transplantation (2013) (0)
- Multi-Modality Imaging Reveals Structural Centrosome Aberrations As a Potential Driver of Chromosomal Instability in Early-Stage Plasma Cell Disorders (2021) (0)
- Pre-Conditioning Serum Leptin Levels Predict Early Relapse Rates of High Risk AML after Allogeneic Stem Cell Transplantation (2018) (0)
- Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATCL): A Retrospective Study of the European Group for Blood and Marrow Transplantation (EBMT) (2011) (0)
- Cytokeratin (CK)-18 and CK18 Fragments As Sensitive and Specific Biomarkers of Acute Hepato-Intestinal Gvhd: Results of a Prospective Observational Study (2015) (0)
- Comparative analysis of minimal residual disease by 4 color flow cytometry (4CFC) and quantitative IgH PCR (RQ-PCR) in chronic lymphocytic leukemia (CLL) after stem cell transplantation (SCT). (2004) (0)
- REDUCED INTENSITY ALLOGENEIC SCT ACHIEVES LONG TERM DISEASE CONTROL IN PATIENTS WITH FOLLICULAR LYMPHOMA RELAPSING AFTER A PRIOR AUTOLOGOUS SCT AND MAY OVERCOME THE ADVERSE IMPACT OF EARLY RELAPSE POST AUTOSCT. AN EBMT LYMPHOMA WORKING PARTY ANALYSIS (2014) (0)
- Comparing the value of mono- versus coculture for high-throughput compound screening in hematological malignancies (2023) (0)
- Efficacy Of Azacitidine Versus Low-Dose Cytarabine In Patients With Acute Myeloid Leukemia - A Retrospective Single Center Experience (2013) (0)
- Autologous stem cell transplantation (ASCT) in patients with POEMS syndrome results in durable symptomatic disease control: A retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancies Working Party of the EBMT (2015) (0)
- Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience (2015) (0)
- HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMATOID GRANULOMATOSIS (2011) (0)
- Low Pre-Transplant Testosterone Levels in Male Patients Are Associated with Endothelial Vulnerability and Non-Relapse Mortality after Allogeneic Stem Cell Transplantation (2016) (0)
- The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O007) (2022) (0)
- Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial) (2021) (0)
- Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study (2014) (0)
- The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT (2023) (0)
- The Number of Stem Cell Transplantations During the COVID-19 Pandemic. (2022) (0)
- Relapse incidence and leukemia-free survival (LFS) in patients (pts) older than age 60 with AM undergoing stem cell transplantation: A report of the East German Study Group Hematology and Oncology (OSHO). (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Peter Dreger?
Peter Dreger is affiliated with the following schools:
